SEC Tracker
Get the app

10x Genomics TXG

10x Genomics reports $19.43 million net loss

Form
10-Q
Filed
Importance
Notable
  1. Revenue: $150.67 million for Q3 2026
  2. Net loss: $19.43 million for Q3 2026
  3. Diluted EPS: -$0.15 for Q3 2026
  4. Cash and equivalents: $526.19 million as of Sep 30, 2026

Written from the 10-Q on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when 10x Genomics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 3826 and related industry codes: the same peer list as the financial tables.

  1. Cohu COHU public float $879M, Jun 27, 2025
  2. Aehr Test Systems AEHR public float $671M, Nov 28, 2025
  3. Transcat TRNS public float $670M, Sep 27, 2025
  4. EyePoint EYPT public float $643M, Jun 30, 2025
  5. Onto Innovation ONTO

Data on this page was fetched . The filing on SEC.gov is the record.